Latest Breaking News On - Davidw boyer - Page 1 : comparemela.com

Neurocrine Biosciences, Inc (NASDAQ:NBIX) Expected to Post Q2 2024 Earnings of $1 11 Per Share

Neurocrine Biosciences, Inc (NASDAQ:NBIX) Expected to Post Q2 2024 Earnings of $1 11 Per Share
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesNeurocrine biosciencesNeurocrine bioscienceWilliam blairKevin charles gormanDavidw boyerFirst horizon advisors incCommonwealth equity servicesQuadrant capital groupSecurities exchange commissionEnvestnet portfolio solutions incSunbelt securities incWells fargo companyNeurocrine biosciences incGoldman sachs groupNeurocrine biosciences company profile

Brokers Issue Forecasts for Neurocrine Biosciences, Inc s Q2 2024 Earnings (NASDAQ:NBIX)

Brokers Issue Forecasts for Neurocrine Biosciences, Inc s Q2 2024 Earnings (NASDAQ:NBIX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesDavidw boyerEric benevichNeurocrine bioscienceWilliam blairNeurocrine biosciencesEnvestnet portfolio solutions incJpmorgan chase coCanaccord genuity groupSecurities exchange commissionQuadrant capital groupCommonwealth equity servicesFirst horizon advisors incNeurocrine biosciences company profileNeurocrine biosciences incWells fargo company

Citigroup Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $150 00

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Citigroup from $140.00 to $150.00 in a research report released on Friday, Benzinga reports. The firm currently has a neutral rating on the stock. Other analysts also recently issued research reports about the company. Oppenheimer raised their price objective on Neurocrine Biosciences from […]

Los angelesUnited statesNeurocrine biosciencesDavidw boyerIngrid delaetNeedham companyCantor fitzgeraldVanguard group incNeurocrine biosciences incCapital partnersJpmorgan chase coLos angeles capital managementNeurocrine biosciences company profileBrown advisory incSecurities exchange commissionFree report

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $216 00 by Analysts at Oppenheimer

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Oppenheimer from $200.00 to $216.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities analysts have also weighed in on the company. Wells Fargo & Company upgraded Neurocrine […]

United statesDavidw boyerEric benevichNeurocrine biosciencesGoldman sachs groupCentral pacific bank trust divisionFidelis capital partnersWells fargo companyMediolanum international funds ltdDaiwa securities group incNeurocrine biosciences company profileSecurities exchange commissionNeurocrine biosciences incFree reportModerate buyGet free report

Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $138 00 at BMO Capital Markets

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target raised by stock analysts at BMO Capital Markets from $129.00 to $138.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ price target would suggest a potential downside of 1.93% from […]

United statesNeurocrine biosciencesDavidw boyerEric benevichWells fargo companyQuadrant capital groupSunbelt securities incNeurocrine biosciences incJpmorgan chase coFirst horizon advisors incEnvestnet portfolio solutions incNeedham companySecurities exchange commissionCommonwealth equity servicesGet free reportWells fargo